AbbVie

North Chicago – October 19, 2026 -- AbbVie's investigational dual-targeting therapy ABBV-466 delivered endoscopic remission in 40.5% of Crohn's disease patients at Week 24, against 22.4% for risankizumab and 20.0% for trosunilimab monotherapy, according to Phase 2a TARGET-CD data (NYSE: ABBV).

ABBV-466 clears the Week 12 primary endpoint at 30.2%

At Week 12, the primary endpoint, 30.2% of ABBV-466 patients achieved endoscopic remission. Patients on anti-IL-23 p19 monotherapy (risankizumab) reached 21.3%, and those on anti-α4β7 monotherapy (trosunilimab) reached 18.0%. The gap to both monotherapy arms widened by Week 24.

ABBV-466 combines risankizumab with trosunilimab. AbbVie said its research found α4β7-driven inflammation persisting despite IL-23 p19 inhibition, which led it to add the α4β7 inhibitor to risankizumab.

North Chicago – October 18, 2026 -- AbbVie will present new and updated data on seven solid tumor assets at the 2026 European Society for Medical Oncology (ESMO) Congress, October 23-27 in Madrid, the company's most expansive ESMO program to date. The data span lung, colorectal, ovarian, prostate and gastric cancers, across antibody-drug conjugates (ADCs), bispecific antibodies and combination regimens.

Temab-A posts 30% response rate in colorectal cancer combination

In a Phase 1 study of previously treated advanced colorectal cancer, Temab-A (telisotuzumab adizutecan) at 2.4 mg/kg plus bevacizumab delivered a 30% overall response rate after a median follow-up of 18.2 months. Median overall survival reached 14.7 months with the combination (n=30), against 10.2 months for standard of care (n=20), regardless of c-Met expression. No new safety signals were observed. The combination is now in the global Phase 3 AndroMETa-CRC-560 study.

North Chicago – October 17, 2026 -- AbbVie (NYSE: ABBV) is presenting 20 new scientific abstracts from its inflammatory bowel disease (IBD) portfolio at the 2026 United European Gastroenterology (UEG) Week, held October 17-20 in Barcelona, Spain. The data cover long-term and real-world outcomes for Skyrizi (risankizumab) and Rinvoq (upadacitinib) in Crohn's disease (CD) and ulcerative colitis (UC).

Risankizumab maintains remission in UC through week 96

In the COMMAND study, patients on risankizumab 180 mg reached as-observed clinical remission rates of 54.0%-73.1% at week 96. Endoscopic remission rates were 38.8%-53.5%. The ranges span advanced therapy-naïve and advanced therapy-experienced patients, and the study reports up to three years of maintenance treatment.

Rockville, Md. – October 12, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will host a three-hour investor event on October 20, 2026 to review its wet age-related macular degeneration (wet AMD) gene therapy program, with topline pivotal data anticipated in the fourth quarter of 2026.

Event runs 1:00 p.m. to 4:00 p.m. ET in New York and online

The session will be held in person in New York and streamed by webcast. It will cover the clinical program for surabgene lomparvovec (sura-vec, ABBV-RGX-314), which REGENXBIO is developing in collaboration with AbbVie.

Management and five retina specialists to address commercial readiness

REGENXBIO management and retina specialists will discuss the treatment landscape, unmet need, the ATMOSPHERE and ASCENT pivotal trials, and the commercial readiness of sura-vec in wet AMD.

Five key opinion leaders are scheduled to appear:

Delray Beach, Fla. – – October 07, 2026 -- The global Active Pharmaceutical Ingredients (API) market will grow from USD 149.02 billion in 2026 to USD 199.42 billion by 2031, a 6.0% compound annual growth rate, according to new data from MarketsandMarkets.

North America commands 43.1% of global API sales as domestic manufacturing investment accelerates

North America held the largest regional share of the API market in 2025 at 43.1%, driven by established pharmaceutical R&D infrastructure and rising investment in domestic production capacity. The US leads regional output in high-value and complex API development, supported by a dense base of pharmaceutical companies, contract manufacturing organizations, and specialized API producers.

North Chicago / Copenhagen – October 05, 2026 -- AbbVie and Genmab A/S reported that epcoritamab combined with standard R-CHOP chemotherapy reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients, based on topline Phase 3 data.

Trial hits statistical significance with hazard ratio of 0.49

The Phase 3 EPCORE DLBCL-2 study showed a hazard ratio of 0.49 (95% CI 0.36-0.67; p-value less than 0.0001) for progression-free survival in patients with an International Prognostic Index (IPI) score of 2 to 5. For the trial's primary endpoint population, patients with IPI scores of 3 to 5, the hazard ratio was also 0.49 (95% CI 0.35-0.69; p-value less than 0.0001).

North Chicago, Ill. – – September 28, 2026 -- AbbVie (NYSE: ABBV) has secured U.S. FDA approval for JUVMO (tavapadon), the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease, with commercial availability set for October 2026.

JUVMO targets dopamine pathways differently than existing D2/D3 agonists

Roopal Thakkar, AbbVie's chief scientific officer, called the approval the first dopaminergic breakthrough for Parkinson's disease in decades. The once-daily oral tablet can be taken with or without levodopa, positioning it across the full disease continuum rather than a single treatment stage.

Rockville, Md. – September 24, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) reported that 60% of Dose Level 3 participants with three-year follow-up data in its Phase II ALTITUDE study achieved a greater-than-2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) after a single in-office treatment with investigational gene therapy sura-vec, with no vision-threatening events recorded among responders.

Three-year data confirm durable DRSS improvement without repeat injections

In long-term follow-up as of August 17, 2026, six of ten Dose Level 3 participants with non-proliferative diabetic retinopathy (NPDR) who reached the three-year visit sustained a greater-than-2-step DRSS improvement without additional diabetic retinopathy treatment. The suprachoroidal delivery used Dose Level 3 (1.0x10^12 GC/eye) combined with short-course prophylactic topical steroids.

North Chicago, Ill. – September 07, 2026 -- Allergan Aesthetics, an AbbVie company, has released a global study of more than 12,000 beauty-involved consumers across nine markets showing a decisive shift away from one-time aesthetic procedures toward personalized, long-term treatment plans.

Global survey data points to a structural change in patient demand patterns

The Layered Beauty: The New Aesthetic Mindset report, based on the 12,000-consumer dataset combined with practitioner input and regional analysis, finds patients increasingly expect multimodal treatment strategies that evolve with their goals and life stages rather than single-session fixes.

Skin quality now anchors broader aesthetic and wellness spending

Respondents identified skin quality as the foundation of aesthetic care, integrating treatments into wider beauty and wellness routines rather than treating them as isolated interventions.